机构

• 合肥物质科学研究院 [11]
• 上海药物研究所 [1]

采集方式

• OAI收割 [12]

内容类型

• 期刊论文 [12]

发表日期

• 2024 [2]
• 2022 [4]
• 2021 [5]
• 2014 [1]

学科主题

筛选

浏览/检索结果: 共12条，第1-10条 帮助 条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择题名升序题名降序提交时间升序提交时间降序作者升序作者降序发表日期升序发表日期降序 A proteogenomic analysis of cervical cancer reveals therapeutic and biological insights 期刊论文  OAI收割 NATURE COMMUNICATIONS, 2024, 卷号: 15, 期号: 1, 页码: 23 作者:  Yu, Jing;  Gui, Xiuqi;  Zou, Yunhao;  Liu, Qian;  Yang, Zhicheng   |  收藏  |  浏览/下载：12/0  |  提交时间：2025/01/06 Efficacy, safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer: an open-label, multicenter, phase Ib trial 期刊论文  OAI收割 CANCER COMMUNICATIONS, 2024 作者:  Zuo, Jing;  Duan, Wei;  Zhao, Mingxuan;  Chen, Zhendong;  Lin, Jie   |  收藏  |  浏览/下载：3/0  |  提交时间：2024/11/22 Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial 期刊论文  OAI收割 ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 18 作者:  Li, Ning;  Zhu, Jianqing;  Yin, Rutie;  Wang, Jing;  Pan, Lingya   |  收藏  |  浏览/下载：37/0  |  提交时间：2022/12/23 Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial 期刊论文  OAI收割 JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40 作者:  Li, Ning;  Zhang, Youzhong;  Wang, Jing;  Zhu, Jianqing;  Wang, Li   |  收藏  |  浏览/下载：112/0  |  提交时间：2022/12/22 Efficacy of niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer in phase 3 PRIME study: A subgroup analysis by response to first-line platinum-based chemotherapy. 期刊论文  OAI收割 JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40 作者:  Yin, Rutie;  Li, Ning;  Wu, Lingying;  Wang, Jing;  Zhu, Jianqing   |  收藏  |  浏览/下载：30/0  |  提交时间：2022/12/23 Olaparib maintenance monotherapy in Chinese patients with platinum-sensitive relapsed ovarian cancer: China cohort from the phase III SOLO2 trial 期刊论文  OAI收割 ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022 作者:  Liu, Jihong;  Yin, Rutie;  Wu, Lingying;  Zhu, Jianqing;  Lou, Ge   |  收藏  |  浏览/下载：64/0  |  提交时间：2022/05/05 BRCA mutation  China  olaparib  ovarian cancer  PARP inhibitor   Efficacy and safety of niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer with complete or partial response to the last platinum-based chemotherapy: a subgroup analysis of the phase III NORA trial 期刊论文  OAI收割 GYNECOLOGIC ONCOLOGY, 2021, 卷号: 162 作者:  Yang, Jiaxin;  Wu, Xiaohua;  Zhu, Jianqing;  Song, Liang;  Feng, Yanling   |  收藏  |  浏览/下载：52/0  |  提交时间：2021/11/01 Fuzuloparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer: a multicenter, randomized, double-blind, placebo-controlled, phase III trial 期刊论文  OAI收割 GYNECOLOGIC ONCOLOGY, 2021, 卷号: 162 作者:  Li, Ning;  Zhang, Youzhong;  Wang, Jing;  Zhu, Jianqing;  Wang, Li   |  收藏  |  浏览/下载：79/0  |  提交时间：2021/11/01 Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or > 12 months: a subgroup analysis of the phase III NORA trial 期刊论文  OAI收割 GYNECOLOGIC ONCOLOGY, 2021, 卷号: 162 作者:  Huang, Qidan;  Wu, Xiaohua;  Zhu, Jianqing;  Wang, Danqing;  Yang, Jiaxin   |  收藏  |  浏览/下载：36/0  |  提交时间：2021/11/01 Safety assessment of niraparib individualized starting dose in patients with platinum-sensitive recurrent ovarian cancer: A randomized, double-blind, placebo-controlled, phase III NORA trial. 期刊论文  OAI收割 JOURNAL OF CLINICAL ONCOLOGY, 2021, 卷号: 39 作者:  Wang, Jing;  Wu, Xiaohua;  Zhu, Jianqing;  Yin, Rutie;  Yang, Jiaxin   |  收藏  |  浏览/下载：30/0  |  提交时间：2022/01/10